![Carl Kraus](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Carl Kraus
Technik-/Wissenschafts-/F&E-Leiter bei
i3 Research, Inc.
Vermögen: 1 Mio $ am 30.06.2026
Profil
Carl N.
Kraus was the founder of Arrevus, Inc., founded in 2015, where the titles held included Chairman, President & Chief Executive Officer from 2017 to 2021.
The current job is Medical Director at i3 Research, Inc. Former jobs include Chief Medical Officer at Idera Pharmaceuticals, Inc., Chief Medical Officer at Resilience Government Services, Inc., Chief Medical Officer at Aceragen, Inc. from 2021 to 2023, and Chief Medical Officer at Aquestive Therapeutics, Inc. from 2023 to 2025.
Education includes undergraduate studies at Washington University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.10.2025 | 282.475 ( 0,23 % ) | 1 Mio $ | 30.06.2026 |
Aktive Positionen von Carl Kraus
| Unternehmen | Position | Beginn |
|---|---|---|
i3 Research, Inc.
 i3 Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts oncology, central nervous system, and respiratory research | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Carl Kraus
| Unternehmen | Position | Ende |
|---|---|---|
| AQUESTIVE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 04.11.2025 |
| ACERAGEN, INC. | Technik-/Wissenschafts-/F&E-Leiter | 30.04.2023 |
Arrevus, Inc.
 Arrevus, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapies for orphan infectious diseases | Vorstandsvorsitzender | 31.10.2021 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Technik-/Wissenschafts-/F&E-Leiter | - |
Resilience Government Services, Inc.
 Resilience Government Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as an integrated biopharmaceutical company | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Carl Kraus
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
14
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Aquestive Therapeutics, Inc.
 Aquestive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops & commercializes thin film pharmaceutical and over the counter drug products | Health Technology |
i3 Research, Inc.
i3 Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts oncology, central nervous system, and respiratory research | Commercial Services |
Resilience Government Services, Inc.
Resilience Government Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as an integrated biopharmaceutical company | Health Technology |
Washington University School of Medicine
 Washington University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Arrevus, Inc.
Arrevus, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapies for orphan infectious diseases | Health Technology |
Aceragen, Inc.
 Aceragen, Inc. BiotechnologyHealth Technology Discovers, develops, and commercializes therapeutics for oncology and rare diseases | Health Technology |
